MYH knockdown in pancreatic cancer cells creates an exploitable DNA repair vulnerability

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Pancreatic ductal adenocarcinoma (PDAC) exhibits poor survival rates and chemoresistance.
• MutY-Homolog (MYH), involved in oxidative DNA damage repair, was previously identified as a potential PDAC therapeutic target.
• The precise mechanism of MYH's anti-PDAC effects and methods for its inhibition were unclear.

Purpose of the Study:

• To elucidate the mechanism by which MYH inhibition affects PDAC cells.
• To evaluate the therapeutic potential of MYH inhibition in a PDAC mouse model.
• To assess if MYH inhibition sensitizes PDAC cells to standard chemotherapies.

Main Methods:

• Investigated MYH inhibition's effects on DNA damage and checkpoint activation in PDAC cells.
• Utilized a clinically-relevant PDAC mouse model with therapeutic MYH-siRNA delivery via Star 3 nanoparticles.
• Assessed the combined effects of MYH knockdown with oxaliplatin and olaparib treatments on PDAC cell proliferation and clonogenicity.

Main Results:

• MYH inhibition was shown to induce DNA damage and checkpoint activation in PDAC cells.
• Therapeutic MYH-siRNA delivery increased intratumoural PDAC cell death but did not inhibit overall tumor growth.
• MYH knockdown significantly sensitized PDAC cells to the anti-proliferative and anti-clonogenic effects of oxaliplatin and olaparib.

Conclusions:

• MYH inhibition triggers DNA damage and checkpoint activation, presenting a vulnerability in PDAC.
• Targeting MYH represents a potential novel therapeutic strategy for pancreatic ductal adenocarcinoma.
• Combining MYH inhibition with existing chemotherapies like oxaliplatin and olaparib may enhance treatment efficacy.